Therapeutic Options for COVID-19 Patients - Minnesota Dept. of Health
As we learn more about COVID-19, recommendations and guidance are updated frequently. Please check back often.

Therapeutic Options for COVID-19 Patients

Information about investigational therapeutics to be updated as new information emerges.

On this page:
Monoclonal Antibody (mAb) Treatment
    Monoclonal antibody treatment and SARS-CoV-2 variants
    Ethical guidance and eligibility
    General resources
    Regeneron - Casirivimab and Imdevimab
    Eli Lilly – Bamlanivimab and Etesevimab
Ventilators and Cardiopulmonary Resuscitation
Remdesivir

The Minnesota Resource Allocation Platform is an online tool that connects patients and health care providers with COVID-19 medications.

Monoclonal Antibody (mAb) Treatment

Monoclonal antibody treatments are available through the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for non-hospitalized COVID-19 positive people.

As of June 25, 2021, HHS/ASPR has paused all distribution of bamlanivimab/etesevimab together and etesevimab alone (to pair with existing supplies of bamlanivimab) on a national basis until further notice. In addition, FDA recommends that health care providers nationwide use alternative authorized monoclonal antibody therapies (REGEN-COV, sotrovimab) and not use bamlanivimab/etesevimab. This is because of the increasing prevalence of the SARS-CoV-2 Gamma (P.1) and Beta (B.1.351) variants. These two variants are not thought to be susceptible to bamlanivimab/etesevimab. For more information, please refer to the MDH Health Advisory: Pause on Monoclonal Antibody Treatment Bamlanivimab/Etesevimab (PDF).

Monoclonal antibody treatment and SARS-CoV-2 variants

Certain circulating SARS-CoV-2 viral variants may be associated with resistance to monoclonal antibodies. Health care providers should review the viral neutralization data in the authorized fact sheets for each mAb available under EUA for details regarding specific variants and resistance (see below). Information on the proportion of SARS-CoV-2 variants circulating in the U.S. is available on CDC COVID Data Tracker: Variant Proportions and will be updated regularly.

Variants are increasing in Minnesota, including variants that have decreased susceptibility to bamlanivimab/etesevimab. This is a rapidly evolving area and providers are encouraged to consult with an infectious disease specialist if they have concerns about mAb treatment and variants.

Please note that although sequencing information is helpful on a population level, individual patient results will not be reported back to the provider or submitting laboratory. Whole genome sequencing is not currently approved for use as a diagnostic test to make individual patient treatment decisions. In addition, the lengthy turnaround time for this type of testing means it is unsuitable for treatment decisions involving mAbs, which should be given as soon as possible once a patient has developed symptoms and tests positive.

Ethical guidance and eligibility

General resources

Regeneron – Casirivimab and Imdevimab

Eli Lilly – Bamlanivimab and Etesevimab

Bamlanivimab/etesevimab is now available for use through HHS. Etesevimab may be shipped alone for combination with existing supplies of bamlanivimab or as a combination product.

Ventilators and Cardiopulmonary Resuscitation

Remdesivir

Remdesivir is available through the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for people with severe COVID-19.

Thank you for your continued partnership. For health care questions, please contact the MDH provider hotline at 651-201-5414.

Updated Friday, 23-Jul-2021 15:43:07 CDT